Noted Vaccine Researcher and Leader Kate O'Brien Awarded Sabin's Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award
WASHINGTON, May 13, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O'Brien, MD, MPH, for her research on the pneumococcal vaccine and leadership in global vaccine research and access, and its Rising Star Award to dedicated physician and public health specialist Livancliff Mbianke, MD, MPH, of Cameroon. The awards were presented at a ceremony in the National Academy of Sciences building in Washington D.C.
O'Brien is a pioneering global health leader whose innovative work in vaccine access and policy has transformed immunization programs worldwide.
'I am honored to award the Sabin Gold Medal to Dr. O'Brien for her extensive scientific and humanitarian work, which has significantly contributed to the development, licensure, and global distribution of critical immunizations,' says Amy Finan, Sabin's chief executive officer. 'The breadth and scope of her work — in addition to her leadership in advancing the availability of vaccines for everyone, everywhere — has saved millions of lives around the world.'
O'Brien's interest in vaccines and preventable illness began during her early career as a research pediatrician in Port-au-Prince, Haiti, where almost a third of children admitted to the hospital she worked at died, often from vaccine-preventable diseases. Returning to the U.S. to pursue her infectious disease fellowship, Master of Public Health, and training as an epidemiologist, she then worked for the Johns Hopkins Center for American Indian Health and led groundbreaking clinical trials on the pneumococcal vaccine to establish the vaccine's performance and impact on both disease and on colonization to achieve both individual and population-level protection. O'Brien was appointed Director of Infectious Disease at the Center and led research on vaccine development and implementation for vaccine-preventable diseases disproportionately affecting Indigenous populations. Her work in large-scale vaccine impact studies and clinical trials has been instrumental in the licensure, introduction and global use of vaccines against pneumococcal disease, rotavirus, influenza, and respiratory syncytial virus (RSV)..O'Brien continued her leadership in vaccine development, access, and research in her position as the Executive Director of the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health. She has served on WHO's Strategic Advisory Group of Experts on Immunization (SAGE) and on the board of Gavi, the Vaccine Alliance, where she has influenced vaccine financing, policy development, and global immunization strategies.
In her current role as Director, Immunization, Vaccines and Biologicals for the World Health Organization (WHO), O'Brien leads the global vaccine and immunization strategy. She oversees WHO's work across the vaccine continuum by accelerating new vaccine research and development, advancing vaccine access and equity, introducing new vaccines into country programs, identifying and responding to outbreaks including as WHO's vaccine technical lead during the COVID-19 pandemic, and strengthening immunization program reach in order to maximize the impact of vaccines, even in the most fragile and vulnerable settings.
O'Brien earned her medical degree from McGill University and a Master of Public Health from Johns Hopkins University. She completed her pediatric and infectious disease training at Johns Hopkins Medical Institutions and served as an Epidemic Intelligence Service officer at the U.S. Centers for Disease Control and Prevention (CDC).
'I am deeply grateful for a career working with incredible people around the world, and through them to have life-saving impact,' says O'Brien. 'Vaccines are truly one of science's greatest achievements. It is immensely fulfilling to work on vaccines all the way from development through licensure and dissemination, and to then see them protect the lives and well-being of families. This award is a huge honor, and a tribute to those who have taught me the value of evidence-based courage.'
Sabin's Rising Star Award is intended to encourage and recognize the next generation of vaccine and immunization leaders. Mbianke is a dedicated physician and public health specialist whose work in vaccine access and strengthening health systems has made a profound impact on underserved communities. With expertise in immunization, maternal and child health, and community engagement, Mbianke has played a pivotal role in expanding vaccine coverage and improving health outcomes in Cameroon.
'With his recognized achievements in reducing maternal and child mortality by 50% in remote areas and increasing accessibility of vaccines, Dr. Mbianke is leading innovations around immunization in fragile settings,' says Finan. 'Whether he is delivering vaccines to displaced populations or creating health clinics out of village councils, his creative solutions serve as a model for those working in challenging settings and makes him a Rising Star in global health.'
As Program Country Manager for the COMBAT Project (Community-Based Tracking for Immunization) at the International Vaccine Access Center (IVAC), Mbianke leads efforts to enhance immunization delivery by improving community-based monitoring, engagement, and service delivery strategies. He also serves as Technical Advisor for the World Health Organization's 'Big Catch-Up,' a global initiative aimed at restoring vaccine coverage following pandemic-related disruptions.
Beyond his advisory roles, Mbianke is the CEO of Empower Women Foundation, where he champions maternal and child health initiatives in Cameroon, advocating for sustainable and locally driven health care solutions. His leadership extends to past roles with WHO, Gavi, USAID, and other global health organizations, where he has contributed to immunization policy formulation and innovative strategies to reach zero-dose and under-immunized children.
A graduate of Université de la Montagne Bagante (MD) and Mountain University for Sustainable Studies (MPH), Mbianke combines medical expertise with public health leadership to promote vaccine confidence and equitable access.
'This award is so meaningful,' says Mbianke. 'When you work in settings with such a high burden, sometimes you feel you are not doing enough because you want to improve as many lives as possible. But recognition like the Rising Star award really motivates you. It says you are creating an impact. You are creating a change.'
Awarded annually since 1993 and 2020 respectively, the Albert B. Sabin Gold Medal and Rising Star Award honor individuals who have made extraordinary contributions to immunization and global health. These awards commemorate the legacy of the late Dr. Albert B. Sabin, who discovered the oral polio vaccine and dedicated his life to ensuring everyone in the world had access to vaccines.
Watch the 2025 Albert B. Sabin Gold Medal and Rising Star ceremony on Sabin's YouTube channel.
About the Sabin Vaccine Institute The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X @SabinVaccine.
Media Contact: Monika Guttman Senior Media Relations SpecialistSabin Vaccine Institute+1 (202) 621-1691press@sabin.org
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c995d1e5-eae3-4d74-b2fa-6e7914d38549
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
11 hours ago
- Business Upturn
Sacred Journey Recovery Showcases Wolf Therapy at Empower Collaboration, Uniting with Thought Leaders in Behavioral Health
Vista, Aug. 12, 2025 (GLOBE NEWSWIRE) — At the recent Empower Collaboration event held August 3–6, Sacred Journey Recovery took center stage in a robust conversation around men's mental health and addiction recovery. Hosted at the intersection of innovation and wellness, the event brought together pioneers in behavioral health, recovery, neuroscience, and holistic well-being. Among a distinguished lineup of presenters, including transformational leaders and behavioral health innovators, Sacred Journey Recovery's presence underscored the center's rising profile in the national conversation surrounding men's substance use and mental health treatment. The Empower Collaboration, known for creating a platform where heart-led professionals come together to inspire collective change, attracted hundreds of clinicians, coaches, trauma experts, and advocates. Keynote voices such as David Meltzer, a globally recognized entrepreneur and humanitarian, set the tone for a weekend rooted in purpose, transformation, and unity. Meltzer, who has long championed mental health and service as a business cornerstone, shared the stage with leaders like Rachel Graham, founder of Healing Springs Ranch, and Dr. Josh Schwarzbaum, an ER physician focused on trauma-informed care. Each presentation served as a call to action to rethink behavioral health from a multidimensional lens, merging clinical excellence, community-based healing, and personal purpose. Sacred Journey Recovery contributed to this dialogue by presenting its trailblazing Wolf Therapy initiative. This program has captured attention for its deep therapeutic impact on men healing from substance use disorders and co-occurring trauma. Unlike traditional talk therapy alone, Sacred Journey's Wolf Therapy sessions leverage the nonverbal, intuitive presence of socialized wolves to help clients confront fears, reconnect to their own power, and rewire patterns of detachment. The wolves, provided in collaboration with the Wolf Education Project, are not only symbols of strength and survival but also partners in the recovery process. When clients come face to face with these majestic animals, it invites them into an encounter that bypasses intellectual defenses and awakens emotional truth. This program is part of Sacred Journey Recovery's broader model, which incorporates evidence-based addiction treatment practices such as Dialectical Behavioral Therapy (DBT), Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Narrative Therapy. Unlike conventional facilities, Sacred Journey interweaves these modalities into real-world experience through adventure therapy, wilderness outings, rites of passage weekends, and brotherhood-based peer support. Based in Vista, California, the center provides a safe space where men are called into deeper self-awareness, radical honesty, and transformative accountability. As the nation confronts an epidemic of fentanyl, methamphetamine, alcohol, and prescription drug abuse—especially among men who have long felt disconnected from traditional therapeutic models—Sacred Journey is positioning itself as a leader in experiential, masculine-centered recovery. The Empower Collaboration was a fitting venue for this work to be highlighted. At a time when many are questioning the efficacy of outdated treatment systems, the event made it clear that innovation is not only welcome—it is essential. CEO Drew Anagnostou shared his appreciation for the experience, stating, 'We are so grateful to be here at the Empower Collaboration event. Being able to share the stage with amazing thought leaders in the space is humbling and invigorating. Sacred Journey Recovery is poised to bring clinical excellence with holistic healing to men across the United States, based right here in Vista, California. We aim to help men reconnect with their authentic masculinity through outdoor-based adventure therapy, while also leveraging industry-leading technologies like Brain Mapping and cutting-edge therapies.' With the national spotlight growing brighter on men's mental health and substance use, Sacred Journey Recovery's participation in the Empower Collaboration signals that the field is evolving. The presence of wolves in a therapeutic setting may seem unconventional to some, but for those in recovery at Sacred Journey, it is just one of many life-changing encounters on the path to wholeness. As conversations from the August event ripple across the behavioral health landscape, Sacred Journey Recovery remains at the forefront, committed to redefining what meaningful, masculine, and sustainable recovery truly looks like. ### For more information about Sacred Journey Recovery, contact the company here: Sacred Journey RecoveryDrew Anagnostou760-888-5202 [email protected] 161 Thunder Drive #214, Vista, California 92083
Business Upturn
11 hours ago
- Business Upturn
Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029
By GlobeNewswire Published on August 13, 2025, 05:30 IST Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) — North America Leads Today, Asia Pacific to Record Fastest Growth The global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to advance at a resilient CAGR of 11.8% from 2024 to 2029, culminating in a forecasted valuation of US$50.2 billion by the end of the period. This growth is propelled by surging R&D investments in drug discovery, strategic government funding, and the increasing adoption of automation in life sciences research. Download PDF Brochure: What Is Driving the Market Now? HTS adoption is accelerating due to innovations in automation, miniaturization, and high-content screening, which significantly reduce discovery timelines and enhance precision in identifying therapeutic candidates. Grants such as the USD 7.8 million awarded to the University of Pittsburgh for advanced drug discovery systems underscore growing institutional and government commitment to high-impact research. Why Does This Matter for Global Pharma and Biotech Leaders? The market represents a critical enabler for competitive advantage in lead discovery, target validation, compound profiling, and hit identification—processes essential for pipeline acceleration. While high instrument costs remain a barrier, particularly for automated liquid handling and high-resolution imaging systems, emerging markets such as China and India offer lucrative opportunities with strong government support and an expanding pharmaceutical manufacturing base. Who Are the Key Stakeholders? The HTS ecosystem spans pharmaceutical giants, biotechnology innovators, academic institutions, and technology providers, all collaborating to enhance assay development and manage the rising complexity of biological data. The consumables segment—driven by recurring purchases of reagents and kits—dominates the market, ensuring steady demand as HTS workflows expand globally. Request Sample Pages: Where Is Growth Coming From? North America currently leads, fueled by advanced HTS infrastructure, robust funding for life science research, and a thriving biotech sector. Asia Pacific is projected to be the fastest-growing region, supported by a diverse patient base, strong pharmaceutical capabilities, and favorable regulatory environments. How Are Market Leaders Responding? Thermo Fisher Scientific Inc. maintains global leadership through an extensive portfolio of automated systems, screening instruments, and consumables, underpinned by 3% annual R&D investment and strategic alliances. Agilent Technologies, Inc. offers highly customizable workflows via BioTek detection instruments and Gen6 software, strengthened by acquisitions such as e-MSion (US) to enhance mass spectrometry capabilities. Merck KGaA delivers a diverse portfolio of reagents, instruments, software, and services, leveraging global reach and deep customer relationships across pharma, academia, and government sectors. Market Outlook As automation, AI-driven data analysis, and advanced assay development converge, HTS will remain at the forefront of pharmaceutical innovation. Decision-makers who strategically invest in HTS capabilities today will be best positioned to accelerate therapeutic pipelines, capture market share, and deliver faster, more targeted treatments to market. For more information, Inquire Now Discover Connected Healthcare Market Opportunities: Drug Screening Market Carrier Screening Market Cell based Assays Market Label Free Detection Market Life Science Instrumentation Market Get access to the latest updates on High-Throughput Screening Companies and High-Throughput Screening Market Size Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
